GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Purchased by Mizuho Securities USA LLC

Mizuho Securities USA LLC boosted its holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 46.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 43,301 shares of the company’s stock after buying an additional 13,692 shares during the quarter. Mizuho Securities USA LLC’s holdings in GE HealthCare Technologies were worth $3,385,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Continuum Advisory LLC grew its position in GE HealthCare Technologies by 101.8% during the 3rd quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares in the last quarter. Bank of Jackson Hole Trust purchased a new position in GE HealthCare Technologies during the 4th quarter worth approximately $32,000. OFI Invest Asset Management purchased a new position in GE HealthCare Technologies during the 4th quarter worth approximately $34,000. Flagship Wealth Advisors LLC purchased a new position in GE HealthCare Technologies during the 4th quarter worth approximately $34,000. Finally, Avion Wealth grew its position in GE HealthCare Technologies by 497.4% during the 4th quarter. Avion Wealth now owns 460 shares of the company’s stock worth $35,000 after purchasing an additional 383 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on GEHC shares. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $95.00 to $103.00 in a research report on Wednesday, January 8th. Citigroup lifted their price objective on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. The Goldman Sachs Group upgraded shares of GE HealthCare Technologies from a “neutral” rating to a “buy” rating and boosted their price target for the company from $85.00 to $100.00 in a report on Tuesday, March 11th. Finally, Wells Fargo & Company boosted their price target on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $98.75.

GE HealthCare Technologies Stock Down 0.4 %

GEHC stock opened at $81.49 on Monday. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88. GE HealthCare Technologies Inc. has a 1 year low of $74.51 and a 1 year high of $94.80. The company has a fifty day simple moving average of $87.02 and a 200 day simple moving average of $86.02. The firm has a market cap of $37.27 billion, a PE ratio of 18.82, a PEG ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The business had revenue of $5.32 billion during the quarter, compared to analyst estimates of $5.33 billion. Sell-side analysts anticipate that GE HealthCare Technologies Inc. will post 4.68 EPS for the current fiscal year.

GE HealthCare Technologies Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.